表紙
市場調查報告書
商品編碼
1025377

全球鼻咽癌市場(2021-2027)

Nasopharyngeal Cancer Market 2021-2027

出版日期: | 出版商: Orion Market Research Pvt Ltd | 英文 | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

在預測期內,全球鼻咽癌市場規模預計將以 2.6% 的穩定複合年增長率增長。鼻咽癌是一種罕見的癌症,始於鼻後咽部的上部。推動市場增長的因素包括患有鼻咽癌的老年人數量增加、煙草消費增加、健康意識提高和生活方式改變。根據美國癌症研究所的估計,鼻咽癌是世界上第 23 位最常見的癌症,男性第 18 位,女性第 22 位。此外,作為市場增長驅動力的認識不斷提高,導致鼻咽癌診斷和治療的採用增加。另一方面,高昂的治療和藥物成本、對癌症的低認識以及治療的副作用正在阻礙市場增長。此外,預計在醫療機構中採用技術將在預測期內進一步推動市場。

全球鼻咽市場受到 COVID-19 大流行的積極影響。鼻咽癌患者感染冠狀病毒的風險增加,這增加了對鼻咽癌治療和藥物的需求。它對市場產生了積極的影響,並見證了市場的增長。

全球鼻咽癌市場根據癌症類型、診斷方法和治療進行分類。根據癌症類型,市場分為角化鱗狀細胞癌、非角化鱗狀細胞癌、未分化癌和其他(腺癌、腺樣囊性癌)。根據診斷方法,市場分為初始診斷和高級診斷。初步診斷進一步分為鼻鏡檢查、內窺鏡檢查和細針抽吸/針活檢。同樣,高級診斷分為 CT 掃瞄、PET 掃瞄、MRI 掃瞄和骨掃瞄。另一方面,根據治療,市場分為化療、免疫治療、手術、靶向治療和放射治療。

本報告調查了全球鼻咽癌市場,提供了市場概況,分析了市場增長和障礙、市場機會以及按癌症類型/診斷/治療區域劃分的市場規模趨勢和預測。它提供了系統信息,例如例如,競爭情況和主要公司的簡介。

目錄

第 1 章報告概述

第 2 章市場概覽和洞察

  • 調查範圍
  • 分析師洞察和當前市場趨勢

第 3 章競爭形勢

  • 主要公司分析
    • 概述
    • 財務分析
    • SWOT 分析
  • 重要的戰略分析
  • Covid 對主要參與者的影響

第 4 章市場決定因素

  • 動機
  • 抑制因素
  • 市場機會

第 5 章市場細分

  • 按癌症類型
    • 角化鱗狀上皮癌
    • 非角化鱗狀上皮癌
    • 未分化癌
    • 其他(腺癌和腺樣囊性癌)
  • 按診斷方法
    • 初步診斷
    • 高級診斷
  • 按處理方法
    • 化療
    • 免疫療法
    • 放射治療
    • 靶向治療
    • 手術

第 6 章區域分析

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 意大利
    • 西班牙
    • 法國
    • 俄羅斯
    • 其他歐洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 其他亞太地區
  • 其他領域
    • 拉丁美洲
    • 中東和非洲

第 7 章公司簡介

  • BioDiem Ltd.
  • Biocon Ltd.
  • Bristol-Myers Squibb Co.
  • Cyclacel Pharmaceuticals, Inc.
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche Ltd,
  • GlaxoSmithKline Plc
  • Merck & Co., Inc.
  • Novartis AG
  • ONO Pharmaceutical Co., Ltd
  • Pfizer Inc.
  • Sanofi SA
目錄
Product Code: OMR2023793

Global Nasopharyngeal Cancer Market Size, Share & Trends Analysis Report By Cancer Type (Keratinising Squamous Cell Carcinoma, Non-Keratinising Squamous Cell Carcinoma, and Others) By Diagnosis Method (Initial Diagnosis and Advanced Diagnosis) By Therapy (Chemotherapy, Immunotherapy, Radiation Therapy, and Others) Forecast, 2021-2027

The global nasopharyngeal cancer market is anticipated to witness a steady CAGR of 2.6% during the forecast period. Nasopharyngeal cancer is a rare form of cancer that occurs in the nasopharynx, upper part of the pharynx (throat) behind the nose. The factors that are augmenting the growth of the market include the rising geriatric population coupled with nasopharyngeal cancer, high consumption of tobacco, increasing health awareness, and changing lifestyle. According to the American Institute for Cancer Research estimates, Nasopharyngeal cancer is the 23rd most common cancer worldwide, and it is the 18th most commonly occurring cancer in men and the 22nd most commonly occurring cancer in women. Further, the increase in adoption of nasopharyngeal cancer diagnosis and treatment has been witnessed due to the growing awareness which is the factor that is further expected to drive the market growth. Some of the factors such as the high cost of treatment and drugs, low awareness of cancer and an adverse side effect of treatment are hampering the market growth. Besides, the adoption of technologies in healthcare premises is further expected to boost the market during the forecast period.

The global nasopharyngeal market is positively impacted by the COVID-19 pandemic. The demands for treatments and drugs for nasopharyngeal cancer were increased as nasopharyngeal cancer patients were at high risk to get affected with coronavirus. That has positively affected the market, also the growth in the market has witnessed. 

The global nasopharyngeal cancer market is segmented based on cancer type, diagnosis method, and therapy. Based on cancer type, the market is categorized into keratinising squamous cell carcinoma, non-keratinising squamous cell carcinoma, undifferentiated carcinomas, and other (adenocarcinoma and adenoid cystic carcinomas). Based on the diagnosis method, the market is bifurcated into initial diagnosis and advanced diagnosis. The Initial diagnosis is further classified into nasendoscopy, panendoscopy, and fine-needle aspiration/needle biopsy. Similarly, the advanced diagnosis is further classified into CT scan, PET scan, MRI scan, and Bone scan. Whereas, based on therapy, the market is divided into chemotherapy, immunotherapy, surgery, targeted therapy, and radiation therapy.

Geographically market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. North America is the fastest-growing region during the forecast period. The factors that drive the growth of the market in the region include, the increasing cases of nasopharyngeal cancer owing to the high consumption of alcohol, tobacco, and cigarette. Moreover, the nasopharyngeal cancer market in the Asia-Pacific region is expected to dominate the market during the forecast period. Increasing healthcare awareness along with increasing spending on IT and healthcare technologies in developing regions, and a large customer base are the factors that are driving the growth of the market. Nasopharyngeal cancer is generally more common in Southeast Asia, and rising incidence in the region is further expected to boost market growth.

Research Methodology

The market study of the global nasopharyngeal cancer market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to break down the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include

  • Financial reports of companies involved in the market.
  • Whitepapers, research papers, and news blogs.
  • Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

  • Global Nasopharyngeal Cancer Market Research and Analysis by Cancer Type
  • Global Nasopharyngeal Cancer Market Research and Analysis by Diagnosis Method
  • Global Nasopharyngeal Cancer Market Research and Analysis by Therapy

The Report Covers

  • Comprehensive research methodology of the global nasopharyngeal cancer market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global nasopharyngeal cancer market.
  • Insights about market determinants that are stimulating the global nasopharyngeal cancer market.
  • Detailed and extensive market segments with the regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • Impact of COVID-19 on the Global Nasopharyngeal Cancer Industry
  • Recovery Scenario of Global Nasopharyngeal Cancer Industry
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
    • 3.1.1. Overview
    • 3.1.2. Financial Analysis
    • 3.1.3. SWOT Analysis
  • 3.2. Key Strategy Analysis
  • 3.3. Impact of Covid on key players

4. Market Determinants

  • 4.1. Motivators
  • 4.2. Restraints
  • 4.3. Opportunities

5. Market Segmentation

  • 5.1. Global Nasopharyngeal Cancer Market, ByCancer Type
    • 5.1.1. Keratinising Squamous Cell Carcinoma
    • 5.1.2. Non-Keratinising Squamous Cell Carcinoma
    • 5.1.3. Undifferentiated Carcinomas
    • 5.1.4. Other (Adenocarcinoma and Adenoid Cystic Carcinomas)
  • 5.2. Global Nasopharyngeal Cancer Market, By Diagnosis Method
    • 5.2.1. Initial Diagnosis
      • 5.2.1.1. Nasendoscopy
      • 5.2.1.2. Panendoscopy
      • 5.2.1.3. Fine Needle Aspiration/Needle Biopsy
    • 5.2.2. Advanced Diagnosis
      • 5.2.2.1. CT Scan
      • 5.2.2.2. PET Scan
      • 5.2.2.3. MRI Scan
      • 5.2.2.4. Bone Scan
  • 5.3. Global Nasopharyngeal Cancer Market, By Therapy
    • 5.3.1. Chemotherapy
    • 5.3.2. Immunotherapy
    • 5.3.3. Radiation Therapy
    • 5.3.4. Targeted Therapy
    • 5.3.5. Surgery

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Russia
    • 6.2.7. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. South Korean
    • 6.3.5. Rest of Asia-Pacific
  • 6.4. Rest of the World
    • 6.4.1. Latin America
    • 6.4.2. Middle East& Africa

7. Company Profiles

  • 7.1. BioDiem Ltd.
  • 7.2. Biocon Ltd.
  • 7.3. Bristol-Myers Squibb Co.
  • 7.4. Cyclacel Pharmaceuticals, Inc.
  • 7.5. Eli Lilly and Co.
  • 7.6. F. Hoffmann-La Roche Ltd,
  • 7.7. GlaxoSmithKline Plc
  • 7.8. Merck & Co., Inc.
  • 7.9. Novartis AG
  • 7.10. ONO Pharmaceutical Co., Ltd
  • 7.11. Pfizer Inc.
  • 7.12. Sanofi SA

LIST OF TABLES

  • 1. GLOBAL NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS BY CANCER TYPE, 2020-2027 ($ MILLION)
  • 2. GLOBAL KERATINISING SQUAMOUS CELL CARCINOMA MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 3. GLOBAL NON-KERATINISING SQUAMOUS CELL CARCINOMA MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 4. GLOBAL UNDIFFERENTIATED CARCINOMAS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 5. GLOBAL OTHER (ADENOCARCINOMA AND ADENOID CYSTIC CARCINOMAS) MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 6. GLOBAL NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS BYDIAGNOSIS METHOD, 2020-2027 ($ MILLION)
  • 7. GLOBAL INITIAL DIAGNOSIS FOR NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 8. GLOBAL INITIAL DIAGNOSIS FOR NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027 ($ MILLION)
  • 9. GLOBAL ADVANCED DIAGNOSIS FOR NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 10. GLOBAL ADVANCED DIAGNOSIS FOR NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027 ($ MILLION)
  • 11. GLOBAL NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS BY THERAPY, 2020-2027 ($ MILLION)
  • 12. GLOBAL CHEMOTHERAPY IN NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 13. GLOBAL IMMUNOTHERAPY IN NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 14. GLOBAL RADIATION THERAPY IN NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 15. GLOBAL TARGETED THERAPY IN NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 16. GLOBALSURGERY IN NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 17. NORTH AMERICAN NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 18. NORTH AMERICAN NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS BY CANCER TYPE,2020-2027 ($ MILLION)
  • 19. NORTH AMERICAN NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS METHOD, 2020-2027 ($ MILLION)
  • 20. NORTH AMERICAN NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS BY THERAPY, 2020-2027 ($ MILLION)
  • 21. EUROPEAN NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 22. EUROPEAN NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS BYCANCER TYPE,2020-2027 ($ MILLION)
  • 23. EUROPEAN NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS BYDIAGNOSIS METHOD, 2020-2027 ($ MILLION)
  • 24. EUROPEAN NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS BY THERAPY, 2020-2027 ($ MILLION)
  • 25. ASIA-PACIFIC NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 26. ASIA-PACIFIC NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS BYCANCER TYPE, 2020-2027 ($ MILLION)
  • 27. ASIA-PACIFIC NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS BYDIAGNOSIS METHOD,2020-2027 ($ MILLION)
  • 28. ASIA-PACIFIC NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS BYTHERAPY, 2020-2027 ($ MILLION)
  • 29. ASIA-PACIFIC NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS BY END USER, 2020-2027 ($ MILLION)
  • 30. REST OF THE WORLD NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 31. REST OF THE WORLD NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS BYCANCER TYPE, 2020-2027 ($ MILLION)
  • 32. REST OF THE WORLD NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS BYDIAGNOSIS METHOD,2020-2027 ($ MILLION)
  • 33. REST OF THE WORLD NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS BYTHERAPY, 2020-2027 ($ MILLION)

LIST OF FIGURES

1. IMPACT OF COVID-19 ON GLOBAL NASOPHARYNGEAL CANCER MARKET, 2020-2027 (% MILLION)

2. IMPACT OF COVID-19 ON GLOBAL NASOPHARYNGEAL CANCER MARKET BY SEGMENT, 2020-2027 (% MILLION)

  • 3. RECOVERY OF GLOBAL NASOPHARYNGEAL CANCER MARKET, 2020-2027 (%)
  • 4. GLOBAL NASOPHARYNGEAL CANCER MARKET SHARE BY CANCER TYPE,2020 VS 2027 (%)
  • 5. GLOBAL NASOPHARYNGEAL CANCER MARKET SHARE BYDIAGNOSIS METHOD,2020 VS 2027 (%)
  • 6. GLOBAL NASOPHARYNGEAL CANCER MARKET SHARE BY THERAPY,2020 VS 2027 (%)
  • 7. GLOBAL NASOPHARYNGEAL CANCER MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 8. GLOBAL KERATINISING SQUAMOUS CELL CARCINOMA MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
  • 9. GLOBAL NON-KERATINISING SQUAMOUS CELL CARCINOMA MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
  • 10. GLOBAL UNDIFFERENTIATED CARCINOMAS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
  • 11. GLOBAL OTHER (ADENOCARCINOMA AND ADENOID CYSTIC CARCINOMAS) MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
  • 12. GLOBAL INITIAL DIAGNOSIS FOR NASOPHARYNGEAL CANCER MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
  • 13. GLOBAL INITIAL DIAGNOSIS FOR NASOPHARYNGEAL CANCER MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
  • 14. GLOBAL ADVANCED DIAGNOSIS FOR NASOPHARYNGEAL CANCER SHARE BY REGION, 2020-2027 ($ MILLION)
  • 15. GLOBAL ADVANCED DIAGNOSIS FOR NASOPHARYNGEAL CANCER MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
  • 16. GLOBAL CHEMOTHERAPY IN NASOPHARYNGEAL CANCER MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
  • 17. GLOBAL IMMUNOTHERAPY IN NASOPHARYNGEAL CANCER MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
  • 18. GLOBAL RADIATION THERAPY IN NASOPHARYNGEAL CANCER MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
  • 19. GLOBAL TARGETED THERAPY IN NASOPHARYNGEAL CANCER MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
  • 20. GLOBAL SURGERY IN NASOPHARYNGEAL CANCER MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
  • 21. US NASOPHARYNGEAL CANCER MARKET SIZE, 2020-2027 ($ MILLION)
  • 22. CANADA NASOPHARYNGEAL CANCER MARKET SIZE, 2020-2027 ($ MILLION)
  • 23. UK NASOPHARYNGEAL CANCER MARKET SIZE, 2020-2027 ($ MILLION)
  • 24. FRANCE NASOPHARYNGEAL CANCER MARKET SIZE, 2020-2027 ($ MILLION)
  • 25. GERMANY NASOPHARYNGEAL CANCER MARKET SIZE, 2020-2027 ($ MILLION)
  • 26. ITALY NASOPHARYNGEAL CANCER MARKET SIZE, 2020-2027 ($ MILLION)
  • 27. SPAIN NASOPHARYNGEAL CANCER MARKET SIZE, 2020-2027 ($ MILLION)
  • 28. REST OF EUROPE NASOPHARYNGEAL CANCER MARKET SIZE, 2020-2027 ($ MILLION)
  • 29. INDIA NASOPHARYNGEAL CANCER MARKET SIZE, 2020-2027 ($ MILLION)
  • 30. CHINA NASOPHARYNGEAL CANCER MARKET SIZE, 2020-2027 ($ MILLION)
  • 31. JAPAN NASOPHARYNGEAL CANCER MARKET SIZE, 2020-2027 ($ MILLION)
  • 32. SOUTH KOREA NASOPHARYNGEAL CANCER MARKET SIZE, 2020-2027 ($ MILLION)
  • 33. REST OF ASIA-PACIFIC NASOPHARYNGEAL CANCER MARKET SIZE, 2020-2027 ($ MILLION)

34. REST OF THE WORLD NASOPHARYNGEAL CANCER MARKET SIZE, 2021-2027($ MILLION